Promising clinical trial of Vaxine’s Covid-19 vaccine technology

CinnaGen Co. announced that the results of preliminary analysis of data from the ongoing Phase 2 human clinical trial of spikogen vaccine based on Vaxine’s COVID-19 vaccine technology were positive. This vaccine comprises a recombinant spike protein antigen formulated with the proprietary Advax-SM adjuvant. The Phase 2 study was a randomized, double-blind, placebo-controlled trial conducted on 400 volunteers assigned to receive two doses, 21 days apart of  active vaccine or saline placebo in a 3:1 ratio. According to CinnaGen, their vaccine branded as SpikoGen was well tolerated in all participants and showed a promising immunogenicity profile. With positive data from this ongoing Phase 2 study CinnaGen now plans to start a large Phase III clinical trial.